Patent and Exclusivity Status of Essential Medicines for Non-Communicable Disease

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Mackey, Tim K ^a,b   Liang, Bryan A ^a,c,d  

^a CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California at San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BUDESONIDE; CARBOPLATIN; CYTARABINE; DOXORUBICIN; ESSENTIAL DRUG; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE; METFORMIN; SALBUTAMOL; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASES; DRUG ADMINISTRATION ROUTE; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE UTILIZATION; MALIGNANT NEOPLASTIC DISEASE; NICOTINE REPLACEMENT THERAPY; NONCOMMUNICABLE DISEASE; PATENT; REFERENCE DATABASE; RESPIRATORY TRACT DISEASE; VALIDATION PROCESS;

DATABASES AS TOPIC; DISEASE; DRUGS, ESSENTIAL; HUMANS; PATENTS AS TOPIC;

EID: 84870675657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051022     Document Type: Article

References (42)

1. World Health Organization (2011) Global status report on noncommunicable diseases 2010. World Health Organization Website. Available: http://www.who.int/nmh/publications/ncd_report2010/en/. Accessed 1 November 2012.
2. Alawan A (2011) WHO: "NCDs Now the Leading Cause of Deaths Globally" Foreign Affairs Website. Available:http://www.foreignaffairs.com/discussions/interviews/who-ncds-now-the-leading-cause-of-deaths-globally. Accessed 16 July 2012.
3. Daar AS, Singer PA, Leah Persad D, Pramming SK, Matthews DR, et al. (2007) Grand challenges in chronic non-communicable diseases. Nature 450: 494-496 doi:10.1038/450494a.
4. Miranda JJ, Kinra S, Casas JP, Davey Smith G, Ebrahim S, (2008) Non-communicable diseases in low- and middle-income countries: context, determinants and health policy. Trop Med Int Health 13: 1225-1234 doi:10.1111/j.1365-3156.2008.02116.x.
5. World Health Organization (n.d.) The top 10 causes of death. World Health Organization Website. Available:http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 30 July 2012.
6. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, et al. (2007) The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bull World Health Organ 85: 279-288 doi:10.2471/BLT.06.033647.
7. Cameron A, Ewen M, Rossdegnan D, Ball D, Laing R, (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet 373: 240-249 doi:10.1016/S0140-6736(08)61762-6.
8. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HGM, et al. (2011) Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 89: 412-421 doi:10.2471/BLT.10.084327.
9. Mamudu HM, Yang JS, Novotny TE, (2011) UN resolution on the prevention and control of non-communicable diseases: an opportunity for global action. Glob Public Health 6: 347-353 doi:10.1080/17441692.2011.574230.
10. World Health Organization (2008) 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. World Health Organization Website. Available:http://www.who.int/nmh/Actionplan-PC-NCD-2008.pdf. Accessed 16 July 2012.
11. Hoen E, Berger J, Calmy A, Moon S, (2011) Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc 14: 15 doi:10.1186/1758-2652-14-15.
12. Attaran A, (2004) How do patents and economic policies affect access to essential medicines in developing countries? Health Aff (Millwood) 23: 155-166.
13. World Health Organization (2011) WHO Model List of Essential Medicines: 17th list. World Health Organization Website. Available:http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. Accessed 16 July 2012.
14. Mirza Z, (2008) Thirty years of essential medicines in primary health care. East Mediterr Health J 14Suppl: S74-S81.
15. Gill GV, Yudkin JS, Keen H, Beran D, (2011) The insulin dilemma in resource-limited countries. A way forward? Diabetologia 54: 19-24 doi:10.1007/s00125-010-1897-3.
16. Cruz AA, Bousquet PJ, (2009) The unbearable cost of severe asthma in underprivileged populations. Allergy 64: 319-321 doi:10.1111/j.1398-9995.2009.02026.x.
17. Kishore SP, Vedanthan R, Fuster V, (2011) Promoting Global Cardiovascular Health. Journal of the American College of Cardiology 57: 1980-1987 doi:10.1016/j.jacc.2010.12.029.
18. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, et al. (2010) Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 376: 1186-1193 doi:10.1016/S0140-6736(10)61152-X.
19. Mathers CD, Loncar D, (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 3: e442 doi:10.1371/journal.pmed.0030442.
20. IMS (2010) IMS Health Forecasts Global Pharmaceutical Market Growth of 5-7 Percent in 2011, Reaching $880 Billion. IMS Health Website. Available:http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=119717f27128b210VgnVCM100000ed152ca2RCR. Accessed 16 July 2012.
21. World Health Organization (2000) The Use of Essential Drugs. World Health Organization Website Available:http://whqlibdoc.who.int/trs/WHO_TRS_895.pdf. Accessed 16 July 2012.
22. U.S. Food and Drug Administration (2011) Approved Drug Products with Therapeutic Equivalence Evaluations: 31st Edition. US Food and Drug Administration.
23. U.S. Food and Drug Administratio (n.d.) Frequently Asked Questions on Patents and Exclusivity. FDA Website. Available:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed 16 July 2012.
24. Metered Dose Inhalers: The Transition to Ozone-Safe Propellants (n.d.) Metered Dose Inhalers: The Transition to Ozone-Safe Propellants. US EPA Website. Available:http://www.epa.gov/ozone/title6/exemptions/inhalers.html. Accessed 16 July 2012.
25. Mackey TK, Liang BA (2012) Promoting global health: utilizing WHO to integrate public health, innovation and intellectual property. Drug Discov Today. doi:10.1016/j.drudis.2012.06.012.
26. Cohen JC, Illingworth P, (2003) The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements. Dev World Bioeth 3: 27-48.
27. Beran D, McCabe A, Yudkin JS, (2008) Access to medicines versus access to treatment: the case of type 1 diabetes. Bull World Health Organ 86: 648-649.
28. Abegunde D (2011) Background paper: Essential Medicines for Non-Communicable Diseases (NCDs). World Health Organization Website. Available:http://www.who.int/medicines/areas/policy/access_noncommunicable/EssentialMedicinesforNCDs.pdf. Accessed 16 July 2012.
29. Defining and Measuring Access to Essential Drugs, Vaccines, and Health Commodities: Report of the WHO-MSH Consultative Meeting, Ferney-Voltaire, France, December 11-13, 2000 (2000) Ferney-Voltaire, France, December 11-13, 2000. Management Sciences for Health Website. Available:http://www.msh.org/seam/reports/Access_Meeting_Ferney_Voltaire_1.pdf. Accessed 22 October 2012.
30. Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, et al. (2008) Poverty and access to health care in developing countries. Ann NY Acad Sci 1136: 161-171.
31. Chua GN, Hassali MA, Shafie AA, Awaisu A, (2010) A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 95: 229-235 doi:10.1016/j.healthpol.2009.11.019.
32. Patel A, Gauld R, Norris P, Rades T, (2009) "This body does not want free medicines": South African consumer perceptions of drug quality. Health Policy Plan 25: 61-69 doi:10.1093/heapol/czp039.
33. Carrera PM, (2009) Ethical Prescribing. Health Affairs 28: 1861-1862 doi:10.1377/hlthaff.28.6.1861-a.
34. Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, et al. (2011) An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS ONE 6: e19857 doi:10.1371/journal.pone.0019857.
35. Guglietta A, Guerrero M, (2008) Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nature 6: 112-119 doi:10.1038/ncpcardio1424.
36. Steinbrook R, (2009) Drug Shortages and Public Health. N Engl J Med. 361: 1525-1527 doi:10.1056/NEJMp0906922.
37. Connelly P, Quinn BP, (2011) Manufacturing decline yields drug shortages. Science 333: 156-157 doi:10.1126/science.333.6039.156-b.
38. Miano P (2011) Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list. Knowledge Ecology International Website. Available:http://keionline.org/rn2011-1. Accessed 30 July 2012.
39. The patent cliff steepens, (2011) Nat Rev Drug Discov. 10: 12-13 doi:10.1038/nrd3356.
40. Hollis A, Liang BA (2006) An Assessment of the Effect of Authorized Generics on Consumer Prices. Generic Pharmaceutical Association Website. Available:http://www.gphaonline.org/sites/default/files/GPhA_AG_Study.pdf. Accessed 16 July 2012.
41. Pharmaceutical production/supply capacity (2002) Pharmaceutical production/supply capacity. UNCTAD Website. Available:http://www.unctad.org/templates/Page.asp?intItemID=4567&lang=1. Accessed 28 August 2011.
42. Seiter A (2005) HNP Brief #3 Pharmaceuticals: Local Manufacturing. World Bank: 1-5. World Health Organization Website. Available: http://apps.who.int/medicinedocs/documents/s16758e/s16758e.pdf. Accessed 1 November 2012.